St. David's in Austin is the first in country to use new dual catheter to fix heart flutter and AFib at the same time.

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and ...

Philip Taylor; Investor Relations; Pulse Biosciences Inc. Paul Laviolette; Co-Chairman of the Board, President, Chief Executive Officer; Pulse Biosciences Inc. Jon S ...

Company successfully meets key milestone with design lock that integrates and finalizes enhancements to its licensed Apex 6 Radiofrequency (“RF ... advances proprietary sensing and ablation catheter ...

Somashekharayya Hiremath said As an inventor, I have contributed to multiple projects and patents, shaping energy-based ...

Atrial Fibrillation (Afib) is a common, yet serious heart condition that requires proper diagnosis and management strategies.

Pulse Biosciences, Inc. ( NASDAQ: PLSE) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Philip Trip Taylor - Investor Relations Paul LaViolette - Chief Executive Officer and Co-Chairman of ...

Its minimally invasive catheter is designed to reach the arteries ... The company said its approach differs from Medtronic’s radiofrequency- and Recor’s ultrasound-powered devices in that ...

Using a temperature-controlled ablation system for ventricular tachycardia is safe and effective, says new study.

Compared to radiofrequency energy, ultrasound energy has the potential to penetrate the tissue more deeply, which may result in faster procedures with effective nerve ablation. The catheter-based ...

The standard of care now for scar-related VT is to do a procedure where you map it, you figure out electrically where everything is coming from, and you zap it with a radiofrequency catheter. You ...